These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11505710)

  • 1. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy.
    Ritt MJ; Hillebrand-Haverkort ME; ten Veen JH
    Acta Chir Plast; 2001; 43(2):54-6. PubMed ID: 11505710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Facial lipodystrophy in patients with HIV infections troublesome to treat].
    Walther RA
    Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
    Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
    New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary complications in patients with AIDS].
    Oka S
    Kekkaku; 2002 Jan; 77(1):37-40. PubMed ID: 11855078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-associated facial lipoatrophy--review of current therapy options.
    Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
    Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?
    Goulbourne CN; Vaux DJ
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):292-6. PubMed ID: 20074077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
    Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
    Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
    Kong HH; Myers SA
    Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
    Terry L; Sprinz E; Stein R; Medeiros NB; Oliveira J; Ribeiro JP
    Med Sci Sports Exerc; 2006 Mar; 38(3):411-7. PubMed ID: 16540826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
    Cossarizza A; Mussini C; Viganò A
    Bioessays; 2001 Nov; 23(11):1070-80. PubMed ID: 11746223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
    Yki-Järvinen H; Sutinen J; Silveira A; Korsheninnikova E; Fisher RM; Kannisto K; Ehrenborg E; Eriksson P; Hamsten A
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):688-94. PubMed ID: 12615670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications & side effects. Lipodystrophy: yesterday, today and tomorrow.
    TreatmentUpdate; 2004; 16(7):1-3. PubMed ID: 17219683
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lipodystrophy in HIV infected children].
    Popielska J
    Pol Merkur Lekarski; 2008 May; 24(143):408-13. PubMed ID: 18634383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical management of lipid abnormalities in HIV--case studies.
    Peters BS
    Int J STD AIDS; 2005 Oct; 16 Suppl 1():31-3; discussion 33-4, 41-3. PubMed ID: 16238829
    [No Abstract]   [Full Text] [Related]  

  • 18. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy.
    Chuapai Y; Kiertiburanakul S; Malathum K; Sungkanuparph S
    J Med Assoc Thai; 2007 Mar; 90(3):452-8. PubMed ID: 17427520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.